Premium
Characteristics of H elicobacter pylori‐ positive and H elicobacter pylori ‐negative gastric mucosa‐associated lymphoid tissue lymphoma and their influence on clinical outcome
Author(s) -
Choi Yoon Jin,
Kim Nayoung,
Paik Jin Ho,
Kim Jung Mogg,
Lee Sang Hyub,
Park Young Soo,
Hwang JinHyeok,
Kim JinWook,
Jeong SookHyang,
Lee Dong Ho,
Jung Hyun Chae
Publication year - 2013
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12033
Subject(s) - helicobacter pylori , mucosa associated lymphoid tissue , malt lymphoma , gastroenterology , medicine , gastric mucosa , lymphoma , lymphatic system , stomach , odds ratio , cancer , gastritis , lesion , pathology
Abstract Background To compare clinicopathologic and molecular characteristics of low‐grade gastric mucosa‐associated lymphoid tissue lymphoma depending on H elicobacter pylori positivity and to find out a predictive factor for unresponsiveness to H elicobacter pylori eradication therapy in K orea. Methods A total of 53 H elicobacter pylori ‐positive and 13 negative mucosa‐associated lymphoid tissue lymphoma patients were enrolled, and tissues from 21 patients were investigated to examine the presence of t(11;18)(q21;q21) with fluorescence in situ hybridization. C linicopathologic features such as the endoscopic appearance, dominant site of lesion, depth of invasion, clinical stage, and the existence of MALT 1 gene rearrangement were compared between these two groups. Fifty‐six patients who underwent H. pylori eradication therapy were divided into responder and nonresponder groups. The two groups were analyzed to calculate odds ratios for resistance to the eradication. Results Helicobacter pylori ‐negative gastric mucosa‐associated lymphoid tissue lymphoma patients averaged a more advanced clinical stage than H. pylori ‐positive ( p = .023) patients. The frequency of t(11;18)/ API 2‐ MALT 1 did not differ between H. pylori ‐positive (45.5%) and H. pylori ‐negative cases (55.6%). Thirty‐eight of 51 (74.5%) H. pylori ‐positive patients achieved complete regression after the eradication, while 2 of 5 (40%) H. pylori ‐negative patients obtained regression. Presence of lesions in both distal and proximal parts of stomach ( p = .041) and bearing of t(11;18)(q21;q21) ( p = .007) were predictors for nonresponsiveness for H. pylori eradication. Conclusions Helicobacter pylori eradication could be performed as a primary therapy regardless of H. pylori status, and assessing t(11;18)/ API 2‐ MALT 1 would be considered after failure to remission by H. pylori eradication.